Calibre Post Acute: Care Order Violations - NM
The resident, identified as R #16 in the November inspection report, had been taking the same 20-milligram daily dose of escitalopram since arriving at the facility in October 2024. The antidepressant is commonly prescribed for major depressive disorder and anxiety.
On July 28, 2025, the consulting pharmacist recommended the resident be evaluated for a dose reduction. The physician responded by writing "resident with good response, maintain current dose" and "disagree with the pharmacist recommendation."
But the doctor provided no clinical rationale explaining why the dose should remain unchanged.
Federal regulations require physicians to document their reasoning when declining pharmacist recommendations during monthly drug reviews. The missing justification could leave residents on medications they no longer need, potentially causing unnecessary drug interactions or adverse side effects, inspectors noted.
The resident's medication history revealed a complex psychiatric profile. Along with dementia without behavioral disturbance and major depressive disorder, the resident also suffered from insomnia. The facility had prescribed multiple psychiatric medications to address these conditions.
In addition to escitalopram, the resident received oxcarbazepine, an anticonvulsant that was initially ordered for seizure control in October 2024. The medication was discontinued in May 2025, then restarted the same day but with a new purpose: treating depression rather than seizures.
The resident also took trazodone, another antidepressant that doubles as a sleep aid. Originally prescribed in November 2024 as a sleep aide, the medication was reordered in June 2025 specifically for insomnia.
The Director of Nursing confirmed during an October 9 interview that the resident had been taking the same doses of escitalopram and oxcarbazepine since admission nearly a year earlier. She acknowledged the pharmacist's recommendation for a gradual dose reduction and confirmed the physician declined without providing medical justification.
The facility's Medical Director explained during a separate interview that gradual dose reductions for antidepressants should be attempted when residents show no signs of depression. He confirmed that providers were expected to document clinical rationales when refusing such recommendations.
The inspection revealed broader concerns about medication management at the 20-bed facility. Inspectors reviewed three residents with depression and found documentation failures in one case that could affect medication safety across the facility.
Escitalopram, the medication in question, belongs to a class of antidepressants called selective serotonin reuptake inhibitors. While generally well-tolerated, the drug can cause side effects including nausea, drowsiness, and sexual dysfunction. In elderly patients with dementia, prolonged use without medical justification raises questions about whether the benefits continue to outweigh potential risks.
The resident's case illustrates a common challenge in nursing home care: balancing psychiatric medication needs with safety concerns in vulnerable populations. Residents with dementia may be particularly susceptible to medication side effects, making regular reviews and dose adjustments crucial.
The facility's failure to document medical reasoning creates a gap in the resident's care record that could complicate future treatment decisions. Without understanding why the physician believed the current dose was medically necessary, other providers may struggle to make informed adjustments.
Federal inspectors classified the violation as causing minimal harm or potential for actual harm to some residents. The finding suggests systemic issues with the facility's medication review process that could affect other residents receiving psychiatric medications.
The inspection occurred following a complaint, though the report does not specify the nature of the original concern that triggered the federal review.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Calibre Post Acute, LLC from 2025-11-18 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
Calibre Post Acute, LLC in Las Cruces, NM was cited for violations during a health inspection on November 18, 2025.
The antidepressant is commonly prescribed for major depressive disorder and anxiety.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.